{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T04:25:46Z","timestamp":1793939146267,"version":"4.8.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T00:00:00Z","timestamp":1728259200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100001253","name":"Multiple Myeloma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001253","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"DOI":"10.1038\/s41408-024-01156-x","type":"journal-article","created":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T07:02:08Z","timestamp":1728284528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP)"],"prefix":"10.1038","volume":"14","author":[{"given":"Benjamin A.","family":"Derman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7261-1335","authenticated-orcid":false,"given":"Ajay","family":"Major","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Cooperrider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aubrianna","family":"Ramsland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Theodore","family":"Karrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7588-1453","authenticated-orcid":false,"given":"Tadeusz","family":"Kubicki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej J.","family":"Jakubowiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,7]]},"reference":[{"key":"1156_CR1","doi-asserted-by":"publisher","first-page":"5988","DOI":"10.1182\/bloodadvances.2020002827","volume":"4","author":"NC Munshi","year":"2020","unstructured":"Munshi NC, Avet-Loiseau H, Anderson KC, Neri P, Paiva B, Samur M, et al. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma. Blood Adv. 2020;4:5988\u201399.","journal-title":"Blood Adv"},{"key":"1156_CR2","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S1470-2045(21)00535-0","volume":"22","author":"F Gay","year":"2021","unstructured":"Gay F, Musto P, Rota-Scalabrini D, Bertamini L, Belotti A, Galli M, et al. Carfilzomib with cyclophosphamide and dexamethasone or lenalidomide and dexamethasone plus autologous transplantation or carfilzomib plus lenalidomide and dexamethasone, followed by maintenance with carfilzomib plus lenalidomide or lenalidomide alone for patients with newly diagnosed multiple myeloma (FORTE): a randomised, open-label, phase 2 trial. Lancet Oncol. 2021;22:1705\u201320.","journal-title":"Lancet Oncol"},{"key":"1156_CR3","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1200\/JCO.20.01814","volume":"39","author":"H Avet-Loiseau","year":"2021","unstructured":"Avet-Loiseau H, San-Miguel J, Casneuf T, Iida S, Lonial S, Usmani SZ, et al. Evaluation of sustained minimal residual disease negativity with daratumumab-combination regimens in relapsed and\/or refractory multiple myeloma: analysis of POLLUX and CASTOR. J Clin Oncol. 2021;39:1139\u201349.","journal-title":"J Clin Oncol"},{"key":"1156_CR4","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1182\/blood.2020010439","volume":"139","author":"J San-Miguel","year":"2022","unstructured":"San-Miguel J, Avet-Loiseau H, Paiva B, Kumar S, Dimopoulos MA, Facon T, et al. Sustained minimal residual disease negativity in newly diagnosed multiple myeloma and the impact of daratumumab in MAIA and ALCYONE. Blood. 2022;139:492\u2013501.","journal-title":"Blood"},{"key":"1156_CR5","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1182\/blood-2018-06-858613","volume":"132","author":"A Perrot","year":"2018","unstructured":"Perrot A, Lauwers-Cances V, Corre J, Robillard N, Hulin C, Chretien M-L, et al. Minimal residual disease negativity using deep sequencing is a major prognostic factor in multiple myeloma. Blood. 2018;132:2456\u201364.","journal-title":"Blood"},{"key":"1156_CR6","doi-asserted-by":"publisher","first-page":"e422","DOI":"10.1016\/S2352-3026(21)00130-7","volume":"8","author":"B Diamond","year":"2021","unstructured":"Diamond B, Korde N, Lesokhin AM, Smith EL, Shah U, Mailankody S, et al. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2021;8:e422\u2013e432.","journal-title":"Lancet Haematol"},{"key":"1156_CR7","unstructured":"Paiva B, Puig N, Cedena M-T, Rosi\u00f1ol L, Cord\u00f3n L, Vidriales M-B et al. Measurable residual disease by next-generation flow cytometry in multiple myeloma. JCO. 2019."},{"key":"1156_CR8","doi-asserted-by":"publisher","first-page":"3279","DOI":"10.1200\/JCO.2017.72.6679","volume":"35","author":"PL McCarthy","year":"2017","unstructured":"McCarthy PL, Holstein SA, Petrucci MT, Richardson PG, Hulin C, Tosi P, et al. Lenalidomide maintenance after autologous stem-cell transplantation in newly diagnosed multiple myeloma: a meta-analysis. J Clin Oncol. 2017;35:3279\u201389.","journal-title":"J Clin Oncol"},{"key":"1156_CR9","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S1470-2045(18)30687-9","volume":"20","author":"GH Jackson","year":"2019","unstructured":"Jackson GH, Davies FE, Pawlyn C, Cairns DA, Striha A, Collett C, et al. Lenalidomide maintenance versus observation for patients with newly diagnosed multiple myeloma (Myeloma XI): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2019;20:57\u201373.","journal-title":"Lancet Oncol"},{"key":"1156_CR10","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1056\/NEJMoa2204925","volume":"387","author":"PG Richardson","year":"2022","unstructured":"Richardson PG, Jacobus SJ, Weller EA, Hassoun H, Lonial S, Raje NS, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N. Engl J Med. 2022;387:132\u201347.","journal-title":"N. Engl J Med"},{"key":"1156_CR11","doi-asserted-by":"publisher","unstructured":"Jasielec J, Kubicki T, Raje N, Vij R, Reece D, Berdeja JG et al. Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma. Blood. 2020. https:\/\/doi.org\/10.1182\/blood.2020007522.","DOI":"10.1182\/blood.2020007522"},{"key":"1156_CR12","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1182\/blood.2023022080","volume":"143","author":"M D\u2019Agostino","year":"2024","unstructured":"D\u2019Agostino M, Bertuglia G, Rota-Scalabrini D, Belotti A, Mor\u00e8 S, Corradini P, et al. Predictors of unsustained measurable residual disease negativity in patients with multiple myeloma. Blood. 2024;143:592\u20136.","journal-title":"Blood"},{"key":"1156_CR13","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1182\/blood.2023022083","volume":"143","author":"C Guerrero","year":"2024","unstructured":"Guerrero C, Puig N, Cedena M-T, Calasanz M-J, Gutierrez NC, Fernandez M, et al. Predictors of unsustained measurable residual disease negativity in transplant-eligible patients with multiple myeloma. Blood. 2024;143:597\u2013603.","journal-title":"Blood"},{"key":"1156_CR14","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1111\/j.1600-0609.2011.01665.x","volume":"87","author":"AK Kvam","year":"2011","unstructured":"Kvam AK, Fayers PM, Wisloff F. Responsiveness and minimal important score differences in quality-of-life questionnaires: a comparison of the EORTC QLQ-C30 cancer-specific questionnaire to the generic utility questionnaires EQ-5D and 15D in patients with multiple myeloma. Eur J Haematol. 2011;87:330\u20137.","journal-title":"Eur J Haematol"},{"key":"1156_CR15","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1111\/ejh.13316","volume":"103","author":"K Sully","year":"2019","unstructured":"Sully K, Trigg A, Bonner N, Moreno-Koehler A, Trennery C, Shah N, et al. Estimation of minimally important differences and responder definitions for EORTC QLQ-MY20 scores in multiple myeloma patients. Eur J Haematol. 2019;103:500\u20139.","journal-title":"Eur J Haematol"},{"key":"1156_CR16","doi-asserted-by":"publisher","first-page":"e1169","DOI":"10.1200\/JOP.19.00639","volume":"16","author":"Y Yu","year":"2020","unstructured":"Yu Y, Brown Wade N, Hwang AE, Nooka AK, Fiala MA, Mohrbacher A, et al. Variability in cytogenetic testing for multiple myeloma: a comprehensive analysis from across the United States. JCO Oncol Pract. 2020;16:e1169\u2013e1180.","journal-title":"JCO Oncol Pract"},{"key":"1156_CR17","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1182\/blood-2022-167382","volume":"140","author":"L Notarfranchi","year":"2022","unstructured":"Notarfranchi L, Zherniakova A, Lasa M, Puig N, Cedena MT, Martinez-Lopez J, et al. Ultra-sensitive assessment of measurable residual disease (MRD) in peripheral blood (PB) of multiple myeloma (MM) patients using bloodflow. Blood. 2022;140:2095\u20137.","journal-title":"Blood"},{"key":"1156_CR18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1182\/blood.2022019531","volume":"142","author":"L Rosi\u00f1ol","year":"2023","unstructured":"Rosi\u00f1ol L, Oriol A, R\u00edos R, Blanchard MJ, Jarque I, Bargay J, et al. Lenalidomide and dexamethasone maintenance with or without ixazomib, tailored by residual disease status in myeloma. Blood. 2023;142:1518\u201328.","journal-title":"Blood"},{"key":"1156_CR19","doi-asserted-by":"publisher","unstructured":"Costa LJ, Chhabra S, Medvedova E, Dholaria BR, Schmidt TM, Godby KN et al. Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trial. Lancet Haematol. 2023. https:\/\/doi.org\/10.1016\/S2352-3026(23)00236-3.","DOI":"10.1016\/S2352-3026(23)00236-3"},{"key":"1156_CR20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S1470-2045(22)00738-0","volume":"24","author":"D Dytfeld","year":"2023","unstructured":"Dytfeld D, Wr\u00f3bel T, Jamroziak K, Kubicki T, Robak P, Walter-Croneck A, et al. Carfilzomib, lenalidomide, and dexamethasone or lenalidomide alone as maintenance therapy after autologous stem-cell transplantation in patients with multiple myeloma (ATLAS): interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023;24:139\u201350.","journal-title":"Lancet Oncol"},{"key":"1156_CR21","doi-asserted-by":"publisher","first-page":"7502","DOI":"10.1200\/JCO.2024.42.16_suppl.7502","volume":"42","author":"P Rodr\u00edguez-Otero","year":"2024","unstructured":"Rodr\u00edguez-Otero P, Moreau P, Dimopoulos MA, Beksac M, Perrot A, Broijl A, et al. Daratumumab (DARA) + bortezomib\/lenalidomide\/dexamethasone (VRd) in transplant-eligible (TE) patients (pts) with newly diagnosed multiple myeloma (NDMM): analysis of minimal residual disease (MRD) in the PERSEUS trial. JCO. 2024;42:7502.","journal-title":"JCO"},{"key":"1156_CR22","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.3324\/haematol.2009.018689","volume":"95","author":"A Caraux","year":"2010","unstructured":"Caraux A, Klein B, Paiva B, Bret C, Schmitz A, Fuhler GM, et al. Circulating human B and plasma cells. Age-associated changes in counts and detailed characterization of circulating normal CD138\u2212 and CD138+ plasma cells. Haematologica. 2010;95:1016\u201320.","journal-title":"Haematologica"},{"key":"1156_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-017-00296-y","volume":"8","author":"L Rasche","year":"2017","unstructured":"Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, et al. Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing. Nat Commun. 2017;8:268.","journal-title":"Nat Commun"},{"key":"1156_CR24","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1016\/j.yao.2022.02.012","volume":"2","author":"BA Derman","year":"2022","unstructured":"Derman BA, Jakubowiak AJ. Moving toward a cure in multiple myeloma: eradication of measurable residual disease. Adv Oncol. 2022;2:159\u201369.","journal-title":"Adv Oncol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01156-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01156-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,7]],"date-time":"2024-10-07T07:02:39Z","timestamp":1728284559000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-024-01156-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,7]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1156"],"URL":"https:\/\/doi.org\/10.1038\/s41408-024-01156-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,7]]},"assertion":[{"value":"26 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 October 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.A.D. declares consultancy for Johnson & Johnson, Sanofi, Canopy, and Cota Inc.; independent clinical trial reviewer for BMS; research funding from GSK and Amgen. A.M., J.C., K.J., A.R., Th.K., and Ta.K. have nothing to disclose. A.J.J. declares honoraria and advisory board fees from Abbvie, Amgen, Bristol-Myers Squibb\/Celgene, GlaxoSmithKline, Gracell, Janssen, and Sanofi.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"170"}}